Summary
The possibility of a pharmacokinetic interaction between isosorbide-5-mononitrate (5-ISMN) and epinine, the active metabolite of ibopamine, has been investigated in 8 healthy male subjects given single doses of 200 mg ibopamine and 20 mg 5-ISMN, separately and together.
The plasma 5-ISMN concentration-time profile was the same whether 5-ISMN was administered concomitantly with ibopamine or alone [AUC(o-t): 2.24 μg·ml−1·h after 5-ISMN alone, 2.16 μg·ml−1·h after 5-ISMN + ibopamine]. The plasma concentrations of total and free epinine and the urinary recovery of total epinine, homovanillic acid and dihydroxyphenylacetic acid, too, were not different when ibopamine was administered alone or concomitantly with 5-ISMN. The intake of ibopamine did not change the blood pressure and heart rate. The decrease in diastolic blood pressure induced by 5-ISMN was not influenced by concomitant intake of ibopamine.
The observations suggest that in healthy volunteers there is no pharmacokinetic interaction between 5-ISMN and ibopamine.
Similar content being viewed by others
References
Abrams J (1980) Nitroglycerin and long-acting nitrates. N Engl J Med 302: 1234–1237
Azzollini F, De Caro L, Longo A, Pelosi G, Rolandi E, Ventresca GP, Lodola E (1988) Ibopamine kinetics after single and multiple dosing in patients with congestive heart failure. Int J Clin Pharmacol Ther Tox 26: 544–551
Dei Cas L, Manca C, Vasini G, Mansour M, Bernardini B, Visioli O (1980) Non-invasive evaluation of left ventricular function through systolic time intervals following oral administration of SB 7505 in man. Drug Res 30: 498–500
Henwood JM, Todd PA (1988) Ibopamine, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 36: 11–31
Lodola E, Borgia M, Longo A, Pocchiari F, Pataccini R, Sher D (1986) Ibopamine kinetics after a single oral dose in healthy volunteers. Drug Res 36: 345–348
Longhini C, Musacci GF, Ansani L, Toselli T, Artiolli T, Bianco L, Ghirardi P (1983) Effect of ibopamine on peripheral haemodynamics. Eur J Clin Pharmacol 24: 585–589
Major RM, Taylor T, Chasseaud LF, Darragh A, Lambe RF (1984) Isosorbide 5-mononitrate kinetics. Clin Pharmacol Ther 35: 653–659
Ochs HR, Neugebauer G, Greenblatt DJ, Labedzki L (1986) Influence of beta-blocker coadministration on the kinetics of isosorbide mononitrate and dinitrate. Klin Wochenschr 64: 1213–1216
Packer M (1983) New perspectives on therapeutic application of nitrates and vasodilator agents for severe chronic heart failure. Am J Med 74: 61–72
Pocchiari F, Pataccini R, Castelnovo P, Longo A, Casagrande C (1986) Ibopamine, an orally active dopamine-like drug: metabolism and pharmacokinetics in rats. Drug Res 36: 334–340
Rosseel MT, Bogaert MG (1979) Simultaneous determination of isosorbide dinitrate and its mononitrates in human plasma by capillary column GLC. J Pharm Sci 68: 659–660
Scott SC, Locke-Haydon J, Pready NS, Buller NP, Cregeen RJ (1987) Ibopamine (SKαF 100168) pharmacokinetics in relation to the timing of meals. Br J Clin Pharmacol 23: 585–587
Taylor T, Taylor IW, Chasseaud LF, Bonn R (1987) Pharmacokinetics and metabolism of organic nitrate vasodilators. In: Bridges JW, Chasseaud LF, Gibson GG (eds) Progress in drug metabolism, vol 10, Taylor and Francis, London, pp 207–336
Ventresca GP, Lodola E (1988) Clinical pharmacokinetics of ibopamine on different diseases and conditions. Drug Res 38: 1175–1180
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lefebvre, R.A., De Wilde, G., Rosseel, M.T. et al. Investigation of a possible pharmacokinetic interaction between ibopamine and isosorbide-5-mononitrate. Eur J Clin Pharmacol 42, 549–552 (1992). https://doi.org/10.1007/BF00314867
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314867